Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by CancerSlayeron May 11, 2023 10:59am
256 Views
Post# 35443134

RE:IBRX Crashes as FDA issues CRL

RE:IBRX Crashes as FDA issues CRL

 

Our competition is weakening by the day...either by suboptimal efficacy or initial rejections/CRLs.  Couldn't have a better scenario for TLT.  

In addition to the suboptimal 23% & 19% 12 month CRs for Adstiladrin & Keytruda, respectively, there are some lackluster preliminary results from Janssen's (Pharma division of J&J) Ph 2 SunRISe-1 study, which includes their investigational anti-PD-1 drug, cetrelimab.  In their April 30, 2023 announcement, systemic cetrelimab monotherapy demonstrated only a 38.1% CR to date.  The above study is also investigating a novel type of continuous intravesical therapy using chemo (TAR-200 monotherapy), which has demonstrated promising CR results to date.  However, the treatment involves four consecutive 21 day cycles of TAR-200 (over "84" days of treatment).  Consequently, there have been significant adverse events (AEs).  Initial findings demonstrated that 30.4% of treated patients had experienced AEs of "grade 3 or higher".  A grade 3 AE is severe & generally requires some type of medical intervention, which can include hospitalization.  A grade 4 AE is life-threatening & requires intensive or emergent care.

All things considered, TLT has great potential to be the primary FDA-approved option in the near future.  All imo.  Good luck...

<< Previous
Bullboard Posts
Next >>